Clinical relevance of cytogenetics in myelodysplastic syndromes

Paolo Bernasconi, Marina Boni, Paola Maria Cavigliano, Silvia Calatroni, Ilaria Giardini, Barbara Rocca, Rita Zappatore, Irene Dambruoso, Marilena Caresana

Research output: Chapter in Book/Report/Conference proceedingConference contribution

34 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) are a group of heterogeneous stem cell disorders with different clinical behaviors and outcomes. Conventional cytogenetics (CC) studies have demonstrated that the majority of MDS patients harbor clonal chromosome defects. The probability of discovering a chromosomal abnormality has been increased by fluorescence in situ hybridization (FISH), which has revealed that about 15% of patients with a normal chromosome pattern on CC may instead present cryptic defects. Cytogenetic abnormalities, except for the interstitial long-arm deletion of chromosome 5 (5q-), are not specific for any French-American-British (FAB)/World Health Organization (WHO) MDS subtypes, demonstrate the clonality of the disease, and identify peculiar morphological entities, thus confirming clinical diagnosis. In addition, chromosome abnormalities are independent prognostic factors predicting overall survival and the likelihood of progression in acute myeloid leukemia.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages395-410
Number of pages16
Volume1089
DOIs
Publication statusPublished - Nov 2006

Publication series

NameAnnals of the New York Academy of Sciences
Volume1089
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Myelodysplastic Syndromes
Chromosomes
Cytogenetics
Chromosome Aberrations
Chromosomes, Human, Pair 5
Fluorescence In Situ Hybridization
Acute Myeloid Leukemia
Defects
Stem Cells
Ports and harbors
Stem cells
Survival
Fluorescence
Health

Keywords

  • Chromosomal abnormalities
  • FAB subtype
  • Fluorescence in situ hybridization
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bernasconi, P., Boni, M., Cavigliano, P. M., Calatroni, S., Giardini, I., Rocca, B., ... Caresana, M. (2006). Clinical relevance of cytogenetics in myelodysplastic syndromes. In Annals of the New York Academy of Sciences (Vol. 1089, pp. 395-410). (Annals of the New York Academy of Sciences; Vol. 1089). https://doi.org/10.1196/annals.1386.034

Clinical relevance of cytogenetics in myelodysplastic syndromes. / Bernasconi, Paolo; Boni, Marina; Cavigliano, Paola Maria; Calatroni, Silvia; Giardini, Ilaria; Rocca, Barbara; Zappatore, Rita; Dambruoso, Irene; Caresana, Marilena.

Annals of the New York Academy of Sciences. Vol. 1089 2006. p. 395-410 (Annals of the New York Academy of Sciences; Vol. 1089).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Bernasconi, P, Boni, M, Cavigliano, PM, Calatroni, S, Giardini, I, Rocca, B, Zappatore, R, Dambruoso, I & Caresana, M 2006, Clinical relevance of cytogenetics in myelodysplastic syndromes. in Annals of the New York Academy of Sciences. vol. 1089, Annals of the New York Academy of Sciences, vol. 1089, pp. 395-410. https://doi.org/10.1196/annals.1386.034
Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Giardini I, Rocca B et al. Clinical relevance of cytogenetics in myelodysplastic syndromes. In Annals of the New York Academy of Sciences. Vol. 1089. 2006. p. 395-410. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1386.034
Bernasconi, Paolo ; Boni, Marina ; Cavigliano, Paola Maria ; Calatroni, Silvia ; Giardini, Ilaria ; Rocca, Barbara ; Zappatore, Rita ; Dambruoso, Irene ; Caresana, Marilena. / Clinical relevance of cytogenetics in myelodysplastic syndromes. Annals of the New York Academy of Sciences. Vol. 1089 2006. pp. 395-410 (Annals of the New York Academy of Sciences).
@inproceedings{45b24bb386344412ac874ffa258472d0,
title = "Clinical relevance of cytogenetics in myelodysplastic syndromes",
abstract = "Myelodysplastic syndromes (MDS) are a group of heterogeneous stem cell disorders with different clinical behaviors and outcomes. Conventional cytogenetics (CC) studies have demonstrated that the majority of MDS patients harbor clonal chromosome defects. The probability of discovering a chromosomal abnormality has been increased by fluorescence in situ hybridization (FISH), which has revealed that about 15{\%} of patients with a normal chromosome pattern on CC may instead present cryptic defects. Cytogenetic abnormalities, except for the interstitial long-arm deletion of chromosome 5 (5q-), are not specific for any French-American-British (FAB)/World Health Organization (WHO) MDS subtypes, demonstrate the clonality of the disease, and identify peculiar morphological entities, thus confirming clinical diagnosis. In addition, chromosome abnormalities are independent prognostic factors predicting overall survival and the likelihood of progression in acute myeloid leukemia.",
keywords = "Chromosomal abnormalities, FAB subtype, Fluorescence in situ hybridization, Myelodysplastic syndromes",
author = "Paolo Bernasconi and Marina Boni and Cavigliano, {Paola Maria} and Silvia Calatroni and Ilaria Giardini and Barbara Rocca and Rita Zappatore and Irene Dambruoso and Marilena Caresana",
year = "2006",
month = "11",
doi = "10.1196/annals.1386.034",
language = "English",
isbn = "1573316695",
volume = "1089",
series = "Annals of the New York Academy of Sciences",
pages = "395--410",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Clinical relevance of cytogenetics in myelodysplastic syndromes

AU - Bernasconi, Paolo

AU - Boni, Marina

AU - Cavigliano, Paola Maria

AU - Calatroni, Silvia

AU - Giardini, Ilaria

AU - Rocca, Barbara

AU - Zappatore, Rita

AU - Dambruoso, Irene

AU - Caresana, Marilena

PY - 2006/11

Y1 - 2006/11

N2 - Myelodysplastic syndromes (MDS) are a group of heterogeneous stem cell disorders with different clinical behaviors and outcomes. Conventional cytogenetics (CC) studies have demonstrated that the majority of MDS patients harbor clonal chromosome defects. The probability of discovering a chromosomal abnormality has been increased by fluorescence in situ hybridization (FISH), which has revealed that about 15% of patients with a normal chromosome pattern on CC may instead present cryptic defects. Cytogenetic abnormalities, except for the interstitial long-arm deletion of chromosome 5 (5q-), are not specific for any French-American-British (FAB)/World Health Organization (WHO) MDS subtypes, demonstrate the clonality of the disease, and identify peculiar morphological entities, thus confirming clinical diagnosis. In addition, chromosome abnormalities are independent prognostic factors predicting overall survival and the likelihood of progression in acute myeloid leukemia.

AB - Myelodysplastic syndromes (MDS) are a group of heterogeneous stem cell disorders with different clinical behaviors and outcomes. Conventional cytogenetics (CC) studies have demonstrated that the majority of MDS patients harbor clonal chromosome defects. The probability of discovering a chromosomal abnormality has been increased by fluorescence in situ hybridization (FISH), which has revealed that about 15% of patients with a normal chromosome pattern on CC may instead present cryptic defects. Cytogenetic abnormalities, except for the interstitial long-arm deletion of chromosome 5 (5q-), are not specific for any French-American-British (FAB)/World Health Organization (WHO) MDS subtypes, demonstrate the clonality of the disease, and identify peculiar morphological entities, thus confirming clinical diagnosis. In addition, chromosome abnormalities are independent prognostic factors predicting overall survival and the likelihood of progression in acute myeloid leukemia.

KW - Chromosomal abnormalities

KW - FAB subtype

KW - Fluorescence in situ hybridization

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=33847772851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847772851&partnerID=8YFLogxK

U2 - 10.1196/annals.1386.034

DO - 10.1196/annals.1386.034

M3 - Conference contribution

SN - 1573316695

SN - 9781573316699

VL - 1089

T3 - Annals of the New York Academy of Sciences

SP - 395

EP - 410

BT - Annals of the New York Academy of Sciences

ER -